Effectiveness and safety of a fixed, low-dose perindopril/ indapamide combination in patients with arterial hypertension: real-world clinical practice data (STRATEGYA, a multi-center, open, prospective study)

Abstract

Aim. To study the role of fixed, low-dose perindopril/indapamide combination in the treatment of patients with arterial hypertension (AH) and inadequate blood pressure (BP) control.
Material and methods: In total, 1726 AH patients with inadequate BP control were divided into three subgroups: I – patients with first-diagnosed AH (n=598, 37%), II – patients whose previously taken antihypertensive agent was changed to Noliprel® (n=582, 35%), and III – patients receiving previous antihypertensive therapy and Noliprel® (n=458, 28%). Subgroups were formed by the doctors. All participants were administered Noliprel®; the dose was doubled if one-month treatment was ineffective (Noliprel® forte). Therapy effectiveness was assessed by office BP measurement at baseline, after 1 and 4 months of the treatment. At 14 clinical centers (n=280), more detailed investigation of treatment safety and effectiveness was performed, including 24-hour BP monitoring (BPM) and blood biochemical analysis at visits 1 and 3.
Results. After 4 months of treatment, in the whole group and in subgroups, systolic and diastolic BP levels were significantly reduced, according to office measurement and 24-hour BPM. Noliprel®/Noliprel® forte therapy was safe and well tolerated by the patients.
Conclusion. Fixed combination of antihypertensives (Noliprel®/Noliprel® forte) effectively and safely reduced BP in patients with uncontrolled AH. Noliprel® therapy was associated with target BP level achievement not only in first-diagnosed AH, but also in case of ineffective previous antihypertensive treatment.